Podcast: BioMerieux CEO On Addressing Antibiotic Resistance With Diagnostics
This article was originally published in The Gray Sheet
Earlier this month, the White House hosted a forum on antibiotic stewardship to advance President Obama's national action plan to combat antibiotic resistance. The diagnostics firm bioMerieux participated in the forum and its CEO Stefan Willemsen recently sat down with "The Gray Sheet" to discuss the issue.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.